EUVIMEDOdkrijte EUVIMED
Crossref

miR-363-5p Targets SP1 to Regulate AMPK/mTOR Signaling and Immune Microenvironment in Gastric Cancer

Cui Yang, Lihao Zhou, Zhengwu Zhou, Shengjin Han

Journal of Visualized Experiments · 2026-11-10 · (237)

DOI: 10.3791/73555 ↗

At a glance

Journal article in Journal of Visualized Experiments, published online on 2026-11-10. Written by Cui Yang and 3 co-authors.

PovzetekBibliografski podatkiCiteRelated studies

Abstract (original language)

Gastric cancer (GC) is an aggressive malignancy with a poor prognosis. Although microRNAs and transcription factors contribute to GC progression, the relationship between miR-363-5p and specificity protein 1 (SP1), and its relevance to AMPK/mTOR signaling and the immune microenvironment, remains unclear. This study investigated the miR-363-5p/SP1/AMPK/mTOR axis in GC. SP1 expression and prognosis were analyzed in the TCGA-STAD cohort (375 tumors, 32 normal tissues) and validated by immunohistochemistry in 14 paired tissues and serum ELISA in 9 GC patients and 10 healthy controls. CIBERSORT and Spearman correlation assessed associations of SP1 with immune-cell infiltration and 79 checkpoint genes. STRING, GO, KEGG, and GSEA analyses were performed. qRT-PCR, Western blot, dual-luciferase reporter, CCK-8, and Transwell assays were conducted in HGC-27 and AGS cells, with SP1 overexpression/knockdown rescue experiments. SP1 was upregulated in GC tissues and serum, associated with poor overall survival, and correlated with immune infiltration. MiR-363-5p was downregulated in GC and negatively correlated with SP1 protein; it directly bound the SP1 3'UTR, and its mimic suppressed, whereas its inhibitor promoted GC-cell proliferation and invasion. Inhibiting miR-363-5p increased SP1 and phosphorylated mTOR (Ser2448) and decreased phosphorylated AMPKα (Thr172); SP1 knockdown reversed these changes, and SP1 overexpression rescued them, and p-S6K changed concordantly. miR-363-5p directly targets SP1 to modulate AMPK/mTOR signaling and GC-cell proliferation and invasion. SP1 upregulation is associated with poor prognosis and computational features of the immune microenvironment, and the axis warrants further mechanistic and therapeutic investigation. These observations remain preliminary: pharmacological validation of the AMPK/mTOR pathway, additional gastric cancer cell lines and a normal gastric epithelial line (GES-1), a larger independent clinical cohort with clinicopathological correlation analyses, additional AMPK/mTOR downstream effectors, and independent external validation of the bioinformatics findings in GEO, CPTAC, TIMER, or GEPIA2 are required in future work.

Cite

APA

Yang, C., Zhou, L., Zhou, Z., & Han, S. (2026). miR-363-5p Targets SP1 to Regulate AMPK/mTOR Signaling and Immune Microenvironment in Gastric Cancer. Journal of Visualized Experiments. https://doi.org/10.3791/73555

Vancouver

Yang C, Zhou L, Zhou Z, Han S. miR-363-5p Targets SP1 to Regulate AMPK/mTOR Signaling and Immune Microenvironment in Gastric Cancer. Journal of Visualized Experiments. 2026. doi:10.3791/73555

BibTeX
@article{Yang2026,
  author = {Yang, Cui and Zhou, Lihao and Zhou, Zhengwu and Han, Shengjin},
  title = {miR-363-5p Targets SP1 to Regulate AMPK/mTOR Signaling and Immune Microenvironment in Gastric Cancer},
  journal = {Journal of Visualized Experiments},
  year = {2026},
  number = {237},
  doi = {10.3791/73555}
}
Start for free →